Special Issue

Biomaterials for Cancer Immunotherapy

Message from the Guest Editor

The goal of cancer immunotherapy is to activate the host immune system to recognize and eliminate malignant cells. The term immunotherapy is used broadly to include various vaccine modalities, cytokines, CAR-T cells, NK cell therapies, antibodies that mediate antibody-dependent cellular cytotoxicity, checkpoint inhibitors, oncolytic viruses, and immunomodulators that reverse tumor-induced immunosuppression. Biomaterials can improve the effectiveness of immunotherapy by facilitating selective and improved delivery of the active agent to the target cells and tissue. Enhanced activation of antigen-presenting cells by delivering immunostimulants in nanocarriers and improved activity of checkpoint inhibitors following local sustained delivery are some examples. The focus of this Special Issue on “Biomaterials for Cancer Immunotherapy” is to further highlight, through original research articles as well as comprehensive reviews, the use of biomaterials to improve the safety and efficacy of anticancer immunotherapy.

Guest Editor

Prof. Dr. Jayanth Panyam

Professor and Dean, Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, PA 19140, USA

Deadline for manuscript submissions

closed (1 November 2021)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/68750

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)